Skip to main content

Table 2 Feasibility of outcome measures, planned versus achieved measurements

From: Leucine-enriched essential amino acid supplementation in mechanically ventilated trauma patients: a feasibility study

Outcome measure

Target (%)

Achieved (%)

Comment

Control (n = 4)

Results as range

L-EAA (n = 4)

Results as range

Patients recruited

> 30

9.5% patients recruited

Lower than anticipated

L-EAA supplement

> 70

73% doses given

Unable to give due to GI intolerance

Inflammatory markers and cytokines

> 90

100% samples taken

All required samples were taken

CRP (mg/L)

2–312

42.7–262

Serum albumin (g/L)

22–30

29–39

IL-6 (pg/mL)

11.4–141

9–78.5

IL-10 (pg/mL)

0–137

0–2100

Urine samples (u-urea, 3-MH)

>  80

81% samples taken

CRRT expected in some patients hence > 80% planned

No misplaced samples

Urinary urea (mmol/24 h)

55–269

51–382

3-MH (μmol/24 h)

174–616

144–660

Muscle depth via ultrasound (sum of three sites, planned measurement on alternate days)

>  90

50% measurements completed

Shorter LOS than anticipated

Fewer measurements recommended, i.e. days 1, 7, 10

Muscle depth (cm)

5.34–12.36

4.43–11.93

Protein turnover study

>  80

31% studies completed

Complex, time-consuming

Required 3 staff members for Douglas bag breath collection method and blood sampling. Simpler technique required, whole body vs muscle protein turnover

Protein turnover (g/24 h)

0

−3.9 to −1.73

Nitrogen balance (PENG, g/day)

> 80

81% calculated

CRRT affecting urine sampling, urinary urea

− 10.6 to 7.4

− 7.95 to 11

Nitrogen balance (Deacon, g/day)

> 80

81% calculated

CRRT affecting urine sampling, urinary urea

− 6.2 to 7.4

− 3.3 to 11.2

Katz and Barthel indices

> 90

100% tested

Poor tests in this setting with substantial floor effect

0

0

MRC sum score

> 90

0% completed

No patient passed initial MRC screening questions (8/10 presented with traumatic brain injury)

  1. CRP C-reactive protein, IL-6 interleukin 6, IL-10 interleukin 10, L-EAA leucine-enriched essential amino acid, GI gastrointestinal, CRRT chronic renal replacement therapy, 3-MH 3-methylhistidine, LOS length of stay, MRC Medical Research Council, RFCSA rectus femoris cross-sectional area